Treatment options for locally advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial compares a standard approach (chemotherapy and radiation before surgery) to a more intensive treatment (total neoadjuvant therapy plus radiation) for locally advanced rectal cancer. It aims to see if the stronger treatment helps remove the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old
- Have a confirmed diagnosis of rectal adenocarcinoma (cancer starting in the rectum)
- The tumor's lower edge is within 10 cm of the anus
- Be able to perform most daily activities without lots of help (ECOG 0-1)
- Have not received any prior anti-cancer treatment for this cancer
- Have no distant spread (metastasis) shown on CT/MRI scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy plans given before rectal cancer surgery to see which helps more people and works better for disease control. If you have locally advanced rectal cancer and have not had treatment yet, this study may be an option.
This trial tests whether adding two newer drugs to standard chemotherapy before surgery can shrink rectal tumors more effectively. It is for patients whose tumors are not too low in the rectum and have certain genetic markers.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial compares different combinations of chemotherapy drugs given before surgery to the standard approach of chemoradiation (chemotherapy plus radiation) for rectal cancer that has not spread. The goal is to see if the drug combinations are more effective at shrinking tumors and improving outcomes.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.